Lilly drug slows Alzheimer's by 60% for mildly impaired patients in trial

(Reuters) -Eli Lilly’s experimental drug donanemab slowed the progression of Alzheimer’s by 60% for patients in the earliest stages of the brain-wasting disease, according to trial data presented at a medical meeting on Monday. Read full story

Source : https://www.thestar.com.my/news/world/2023/07/17/lilly-drug-slows-alzheimer039s-by-60-for-mildly-impaired-patients-alzheimer039s-group-says